Nomination period for the Broermann Medical Innovation Award started
- Prize money of one million euros higher than the prize money for the Nobel Prize for Medicine
- Award honors researchers worldwide who have done pioneering work in medicine, biotechnology, or related fields
Gießen, January 17, 2025. The nomination period for the Broermann Medical Innovation Award has started. The prize, which will be awarded for the first time this year, is aimed at scientists worldwide who have carried out pioneering work in medicine, biotechnology, or related fields with their research.
The nomination portal (www.broermann-award.org/nomination/) is open until March 1, 2025. At one million euros, the prize is more valuable than the Nobel Prize for Medicine, making it one of the most highly endowed awards for medical research worldwide.
The international Broermann Medical Innovation Award recognizes research results that demonstrate a high level of innovation for clinical application and thus have the potential to improve the lives and health of millions of people worldwide. The prize is aimed at scientists whose research has been pioneering in the fields of medicine, biotechnology, or related sciences.
The Broermann Medical Innovation Award was established in 2024 to honor the vision and commitment of Dr. Bernard große Broermann, the founder of the Asklepios Kliniken. The Broermann gemeinnützige GmbH sponsors the award, and the University Hospital Giessen and Marburg (UKGM) manages the organization. “With this award, we want to honor groundbreaking medical discoveries and highlight those whose research brings real improvements in the prevention or treatment of diseases,” says Prof. Werner Seeger, Chairman of the Award Committee. For the Medical Director of the UKGM, Prof. Friedrich Grimminger, the unique prize reflects the clear conviction of the company founder: “Scientific excellence in medicine is always an international team effort, but without the genius of individual researchers, networks are limited in their impact. These key players and drivers of medical innovation should be promoted and recognized worldwide.”
Nomination process and deadlines
Nominations for the Broermann Medical Innovation Award can be submitted until March 1, 2025. The incumbent Hessian Minister President will present the award in December 2025 at the Hessian State Chancellery in Wiesbaden.
Further information on the award, the nomination criteria, and the selection process can be found at www.broermann-award.org.
For further information, please contact
Broermann Medical Innovation Award
Mirjam Malko
Tel.: +49 (0) 641 / 985-42310
E-Mail: contact@broermann-award.org
Asklepios Kliniken
Corporate Communications and Marketing
Tel.: + 49 (0) 40 / 18 18-82 66 36
E-Mail: presse@asklepios.com
24-hour on-call service for the press office: +49 (0) 40 / 1818-82 8888
Visit Asklepios on the Internet, Facebook or YouTube:
www.asklepios.com/konzern/gesundheitsmagazin
www.facebook.com/asklepioskliniken
www.youtube.com/asklepioskliniken
RHÖN-KLINIKUM AG
Corporate Communications and Marketing
Heike Ochmann
Press Spokeswoman
Tel.: +49 (0) 9771 / 65-12130
E-Mail: heike.ochmann@rhoen-klinikum-ag.com
MEDICLIN AG
Dr. Janina Lossen
Press Spokeswoman
Tel:. +49 (0) 781 / 488-180
E-Mail: presse@mediclin.de
UKGM
Frank Steibli
Head of Communications and Press Spokesman
Tel.: +49 (0) 641 / 985-51020
Mobile: +49 (0) 160 / 7120456
E-Mail: frank.steibli@uk-gm.de
Nyckelord
As wholly owned subsidiary of dpa, news aktuell provides business and organizations with effective access to media and consumers. Via the smart tools ots and zimpel, PR content accesses all media formats, including classical print, high click-rate online portals and social networks. In addition, news aktuell publishes all its customers’ PR content on www.presseportal.de, one of the PR portals with the greatest reach in Germany. By this means, all the relevant multipliers are reached globally, from editors, via digital influencers right up to specialist bloggers and interested consumers. news aktuell has been on the market since 1989. The company, with a staff complement of more than 135, has its headquarters in Hamburg. Other offices are in Berlin, Dusseldorf, Frankfurt und Munich.
Följ news aktuell GmbH
Abonnera på våra pressmeddelanden. Endast mejladress behövs och den används bara här. Du kan avanmäla dig när som helst.
Senaste pressmeddelandena från news aktuell GmbH
Canary Islands, first European destination in ROBLOX17.1.2025 13:00:00 CET | Press Release
Turismo de Canarias presents Find the Seasouls, an interactive experience within ROBLOX designed to promote environmental care in new generations, calling for respect for natural parks, protected spaces and the biodiversity of the islands
Effective immediately: French purchasing group Francap starts pooling procurement of their strong private label brands under the international umbrella of the EMD Alliance17.1.2025 12:00:00 CET | Pressmeddelande
Pfäffikon/Switzerland, 17/01/2025: Right at the start of 2025, the European Marketing Distribution (EMD) network is once again demonstrating the additional benefits that cooperation between renowned distributors can generate for customers in the retail sector: The latest example is a new cooperation on the joint procurement of private labels in France with the renowned buying group Francap, who serves 10 local retailers, representing over 2,200 points of sale, including the French operations of EMD's Belgian partner Colruyt.
LTS wins funding from BARDA’s Patch Forward Prize Competition for two partnerships14.1.2025 13:05:41 CET | Press Release
Andernach – LTS LOHMANN Therapie-Systeme AG (“LTS”), a leading pharmaceutical technology company, is proud to announces its selection as a Concept Stage winner for two projects in the #PatchForwardPrize, a $50 million challenge by the Biomedical Advanced Research and Development Authority (BARDA) to advance microneedle patch-based RNA vaccine technologies. The Patch Forward Prize, part of the Project NextGen initiative led by BARDA, aims to accelerate next-generation vaccine technologies. By fostering partnerships between vaccine developers and delivery platform innovators, the competition drives progress from concept to clinical stages, paving the way for transformative advancements in global health. Each of the prizes announced today represents an award of US$ 2 million, that will be shared between LTS and its partners. The awarded projects bring together LTS’s proprietary dissolvable Microneedle Array Patch (MAP) technology with mRNA vaccines from two partners, BioNet, a biotech man
FEV develops AI-supported driver monitoring system CogniSafe9.1.2025 11:00:00 CET | Pressmeddelande
Aachen – FEV, a leading global innovation driver for the mobility of tomorrow, presents CogniSafe, a state-of-the-art Driver Monitoring System (DMS) that significantly increases road safety. The system uses advanced technologies such as deep learning and computer vision to monitor driver conditions such as distraction, fatigue and inattention in real time and under even the most challenging conditions.
Grünenthal appoints Prof. Dr. Uli Brödl as Chief Scientific Officer9.1.2025 10:25:56 CET | Press Release
Aachen, Germany, 09 January 2025 – Grünenthal announced today that Prof. Dr. Uli Brödl will assume the role of Chief Scientific Officer (CSO) and Member of the Corporate Executive Board, effective 01 February 2025. Uli Brödl has more than 15 years of industry experience. He joins Grünenthal from Boehringer Ingelheim, where he served as Corporate Senior Vice President, Head of Global Clinical Development & Operations, and member of Boehringer Ingelheim's Venture Fund Investment Committee. In his most recent role, he oversaw end-to-end clinical development and operations activities across therapeutic areas and worked at the interface of R&D, Commercial, and Market Access functions. He has a proven track record of bringing innovative medicines to patients, including Empagliflozin, an oral anti-diabetic medicine. Earlier in his career, Uli Brödl led Boehringer Ingelheim's Canadian medical organisation and gained extensive market experience. In parallel, he founded and co-chaired the BI Can
I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.
Besök vårt pressrum